Hypnion, Inc.

Ore Pharmaceuticals Inc.

Millennium Pharmaceuticals Limited

Michael E Solomon

David G Hangauer

Dale M Edgar

James F White

Kazumi Shiosaki

Michael A Patane

Tricia J Vos

Daniel Coughlin

Christopher Blackburn

Mihaela D Danca

Daniel L Flynn

Bruce D Roth

Bharat Kalidas Trivedi

Kenneth Gordon Carson

Christopher F Claiborne

Susan Laurene Acton

Natalie Alysia Dales

Martin P Maguire

Geraldine C B Harriman

Yuntao Song

Bing Guan

Timothy D Ocain

Thomas H Marsilje, Iii

Alexandra E Gould

Mingshi Dai

Harry Jefferson Leighton

Emmanuel J M Mignot

James A Brown

Christine Nylund Kolz

Kuai-Lin Sun

Alain Stricker-Krongrad

Vivek J Kadambi

Ly Pham

The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.

Benzisoxazole piperidine compounds and methods of use thereof

The invention relates to novel compounds and methods of using them for modulating sleep.

Loxapine analogs and methods of use thereof

The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.

Benzisoxazole piperazine compounds and methods of use thereof

Olanzapine analogs and methods of use thereof

This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I: wherein X is oxygen or sulfur; G is G1 or G2: 

Modulators of melanocortin receptor

Quetiapine analogs and methods of use thereof

The invention relates to novel doxepin analog compounds and methods of modulating sleep by administering such compounds, or a pharmaceutically effective salt thereof.

Doxepin analogs and methods of use thereof

The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.

Provided are MC4-R binding compounds of the formula XVII: wherein Lis a linker group, and P, P, P, P, Z, Z, Z, Z, Z, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.

Melanocortin-4 receptor binding compounds and methods of use thereof

This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I: wherein X is oxygen or sulfur; G is G1 or G2: L, L, Land Q are linker groups, and Rings A, B and C, and R-Rare described in the specification. The compounds are antagonists of melanocortin receptors.

The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.

Treatment of CNS disorders using CNS target modulators

ACE-2 inhibitors for the treatment of body weight and related disorders are disclosed. ACE-2 inhibitors include peptides and small molecules. Examples of small molecule ACE-2 inhibitors include compounds of formula (I):Z-&#x39b;&#x2003;&#x2003;(I)Wherein Z is a zinc coordinating moiety and &#x39b; is an amino-acid mimicking moiety, and pharmaceutically acceptabale salts thereof. Methods of using the inhibitors and pharmaceutical compositions containing the inhibitors to treat a body weight disorder, to decrease appetite, to increase muscle mass, to decrease body fat, to treat diabetes and to treat a state associated with altered lipid metabolism, are also described.

ACE-2 modulating compounds and methods of use thereof

Growing community of inventors

Nashua, NH, United States of America

Michael E Solomon